과민성 방광 치료 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 질환 유형별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Overactive Bladder Treatment Market Growth & Trends:

The global overactive bladder treatment market size is expected to reach USD 5.25 billion by 2030, and is estimated to register a CAGR of 4.8% over the forecast period, according to a new report by Grand View Research, Inc. Factors such as the growing awareness about the overactive bladder (OAB) condition, along with rising R&D investments to develop novel formulations for this disease, are projected to drive the global market. In addition, rising competition owing to high demand for OAB medications and treatments and rising emphasis of major players to manufacture drugs is another vital factor propelling the demand forward.

Rising awareness about OAB and urinary incontinence among the population is one of the major factors bolstering the growth of the market. Various key players operating in the industry undertake numerous initiatives to raise awareness about the overactive bladder condition. For instance, in January 2023, Urovant Sciences, a key player operating in the market, collaborated with actress and patient Holly Robinson Peete under a campaign to bring awareness to OAB. Such initiatives help increase awareness and knowledge about the treatment options thereby increasing treatment adoption.

Moreover, increasing investments to develop innovative formulations and treatments targeting OAB are anticipated to fuel growth over the forecast period. For instance, in November 2019, EBT Medical, Inc., a startup, received funding of USD 10 million in series A for developing noninvasive neuromodulation technology to treat overactive bladder. Thus, developments and investments focusing on medications and treatments are anticipated to fuel the geographic expansion.

Furthermore, industry participants are undertaking various strategies like collaborations and new product launches to maintain their position in this competitive market. For instance, in March 2023, KYORIN Pharmaceutical Co., Ltd. collaborated with Sumitomo Pharma Co., Ltd. to develop, manufacture, and commercialize Vibegron for OAB in Taiwan and other Asian Countries like Singapore, Hong Kong, Indonesia, and Vietnam. Such collaborations among major players are expected to increase the accessibility of drugs and treatments across the countries, which can further propel growth in the coming years.

Overactive Bladder Treatment Market Report Highlights:

• Mirabegron drug dominated the market in 2023 with a which can be attributed to the high adoption and prescription rate of Mirabegron for treating OAB
• Among disease-type segments, the idiopathic overactive bladder segment was the largest revenue contributor for the industry in 2023 due to its high prevalence rate
• In the distribution channel segment, the retail pharmacies dominated the market. The higher revenue growth is attributed to the presence of established retail pharmacies offering OAB drugs and its better patient compatibility
• North America dominated the market for overactive bladder treatment in 2023 owing to the presence of key players such as Pfizer, Inc., AbbVie, Inc., and Viatris, Inc. across the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Segment Definitions
  • 1.1.1. Product Segment
  • 1.1.2. Strength Segment
  • 1.1.3. Distribution Channel Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. Gvr's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations
• 1.12. Research Assumptions

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of target diseases
    • 3.2.1.2. Rising R&D investments for introducing new treatments
    • 3.2.1.3. Growing awareness about the condition
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Adverse effects associated with medications and treatment.
    • 3.2.2.2. Increasing product recalls
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

• 4.1. Overactive Bladder Treatment Market: Type Movement Analysis
• 4.2. Anticholinergics
  • 4.2.1. Anticholinergics Market, 2018 - 2030 (USD Million)
• 4.3. Mirabegron
  • 4.3.1. Mirabegron Market, 2018 - 2030 (USD Million)
• 4.4. Botox
  • 4.4.1. Botox Market, 2018 - 2030 (USD Million)
• 4.5. Neuromodulation
  • 4.5.1. Neuromodulation Market, 2018 - 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Other Types Market, 2018 - 2030 (USD Million)

Chapter 5. Disease Type Business Analysis

• 5.1. Overactive Bladder Treatment Market: Disease Type Movement Analysis
• 5.2. Idiopathic Overactive Bladder
  • 5.2.1. Idiopathic Overactive Bladder Market, 2018 - 2030 (USD Million)
• 5.3. Neurogenic Overactive Bladder
  • 5.3.1. Neurogenic Overactive Bladder Market, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

• 6.1. Overactive Bladder Treatment Market: Distribution Channel Movement Analysis
• 6.2. Hospital Pharmacies
  • 6.2.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.3. Retail Pharmacies
  • 6.3.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 6.4. Others
  • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Overactive Bladder Treatment Market Share By Region, 2023 & 2030
• 7.2. North America
  • 7.2.1. North America Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Competitive Scenario
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. U.S. Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Competitive Scenario
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Canada Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. UK Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Germany Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. France Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Competitive Scenario
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Italy Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Competitive Scenario
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Spain Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Competitive Scenario
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Denmark Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Competitive Scenario
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Sweden Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Competitive Scenario
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Norway Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Japan Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. China Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. India Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.4.5. Australia
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Australia Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.4.6. Thailand
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Thailand Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.4.7. South Korea
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. South Korea Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Brazil Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Mexico Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.5.4. Argentina
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Scenario
    • 7.5.4.5. Argentina Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. South Africa Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Saudi Arabia Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. UAE Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Kuwait Overactive Bladder Treatment Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2023
• 8.4. Company Profiles/Listing
  • 8.4.1. Pfizer, Inc
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. AbbVie Inc.
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Astellas Pharma Inc.
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Medtronic
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Sumitomo Pharma America, Inc.( Urovant Sciences.)
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Viatris Inc.
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Teva Pharmaceutical Industries Ltd.
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Hisamitsu Pharmaceutical Co., Inc.
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Macleods Pharmaceuticals Ltd.
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Endo International plc
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives